Advertisement
Advertisement
September 9, 2025
Varian’s Embozene Approved in Europe for Genicular Artery Embolization
September 9, 2025—Varian, a Siemens Healthineers company, announced that its Embozene microspheres have received European CE Mark approval for genicular artery embolization (GAE) to treat knee osteoarthritis (OA).
According to the company, Embozene is an embolic agent for GAE, intended to target inflammation and help relieve pain in patients with knee OA.
The catheter-based GAE procedure involves the delivery of Embozene microspheres to reduce blood flow to areas of greatest inflammation. With the procedure, the company aims to provide an alternative to joint replacement surgery for patients who have exhausted other measures, noted Varian.
Varian further stated that the company-sponsored GENESIS II trial has completed patient enrollment. The randomized, sham-controlled study will evaluate the safety and efficacy of GAE for knee OA. GENESIS II is led by Principal Investigator Mark Little, MD, at Royal Berkshire Hospital in Reading, United Kingdom.
Embozene is currently marketed in 60 countries for embolization of hypervascular tumors, uterine fibroids, and benign prostatic hyperplasia. Additionally, the FDA granted Breakthrough Device designation for GAE in knee OA in 2021, advised the company.
Advertisement
Advertisement
